Illumina, Inc. vs Quantum Computing Inc — how do they compare? Illumina, Inc. trades at $277.61 (market cap $39.95B), while Quantum Computing Inc trades at $7.46 (market cap $1.69B). The key difference: Illumina, Inc. is far larger — about 23.6× Quantum Computing Inc's market cap, and Illumina, Inc. is trading nearer its 52-week high, Quantum Computing Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Illumina, Inc. for 83 Days and Quantum Computing Inc for 25 Days on average.
| ILMN | QUBT | |
|---|---|---|
Market Cap | $39.95B | $1.69B |
Volume | 3,169,503 | 7,991,522 |
Sector | Health | Technology |
52-Week High | $293.69 | $21.78 |
52-Week Low | $91.00 | $6.31 |
Typical Hold Time | 83 Days | 25 Days |
Enterprise Value | $41.31B | $753.24M |
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $271.02, up 1.22% and near its 52-week high, reflecting strong momentum. The stock exhibits a bullish technical trend with recent earnings beats and a positive analyst consensus. Revenue for 2025 was $4.34B with net income of $850M, marking a significant profit margin recovery. Cash flow from operations remains robust at $1.08B, supporting financial stability. Inclusion in the S&P 500 and focus on AI-driven genomics growth are key catalysts.
Outlook is positive given earnings momentum and strategic initiatives, but risks include valuation premiums and competitive pressures. The stock offers growth exposure to genomic innovation, though investors should monitor execution on AI integration and margin sustainability. Analyst price targets suggest moderate upside from current levels, with consensus at $241.00.
Quantum Computing Inc. (QUBT) trades at $7.43, down 2.49% today, with a bearish technical signal despite bullish oscillators. The company shows explosive revenue growth from $682K in 2025 to $10M projected for 2026, but remains deeply unprofitable with a -152.45% net income margin. Recent developments include the Dirac-3S quantum system launch and a $42.5M backlog, though rising expenses and shareholder litigation create headwinds.
QUBT offers speculative growth potential in quantum computing with strong analyst support (75% buy rating, $17.33 target) but faces significant execution risks. The stock's appeal hinges on commercializing quantum technology amid persistent losses and competitive threats, requiring careful risk assessment by growth-oriented investors.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →Quantum Computing Inc. is a company focused on providing accessible quantum computing and quantum-enhanced software solutions for complex problems. The company's technology is designed to run on both classical and quantum hardware, enabling businesses to explore the power of quantum computing today for applications in finance, drug discovery, and logistics. QUBT offers a platform that makes quantum algorithms and software available through the cloud, aiming to democratize access to this advanced computing paradigm.
Read more on QUBT →